UCL Department of Science, Technology, Engineering and Public Policy


Policy brief: Manufacturing Biological Medicines

Biological medicines are a relatively new class of medicines and represent an increasingly large proportion of goods produced by the pharmaceutical sector and already comprise eight out of the top ten selling medicines by revenue.

In its Industrial Strategy and through the Life Sciences Sector Deal (December 2017), the UK set out its ambition to strengthen the production of such pioneering treatments in the UK. This briefing looks at the growing biomanufacturing sector and some of the technological and regulatory challenges for manufacturing this new class of medicines, as well as some of the opportunities they present for improved health and economic growth.

UCL’s excellence in biomanufacturing based in the Department of Biochemical Engineering is highlighted.


EPSRC and the Department of Health and Social Care

Lead researchers

Professor Paul Dalby, Professor Suzy Farid, Professor Martina Micheletti (UCL Biochemical Engineering), Professor Sarah Gilbert (University of Oxford Jenner Institute)

Output type

Policy brief

PIU lead

Dr Penny Carmichael

Download the Manufacturing Biological Medicines policy brief [PDF]

Last updated: Tuesday, July 6, 2021